Host-directed therapy of tuberculosis based on interleukin-1 and type i interferon crosstalk

Nature

Volumn 511, Issue 7507, 2014, Pages 99-103

  Mayer Barber, Katrin D ^a   Andrade, Bruno B ^a   Oland, Sandra D ^a   Amaral, Eduardo P ^a,b   Barber, Daniel L ^a   Gonzales, Jacqueline ^a   Derrick, Steven C ^c   Shi, Ruiru ^d   Kumar, Nathella Pavan ^e,f   Wei, Wang ^d   Yuan, Xing ^d   Zhang, Guolong ^g   Cai, Ying ^a   Babu, Subash ^a,e   Catalfamo, Marta ^a   Salazar, Andres M ^h   Via, Laura E ^a   Barry Iii, Clifton E ^a   Sher, Alan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d Henan Chest Hospital   (China)

^e International Center for Excellence in Research   (India)

^f NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^g Sino US International Research Center of Tuberculosis   (China)

^h Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYCLOOXYGENASE 2; ICOSANOID; INTERFERON; INTERLEUKIN 1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOTHERAPY; DISEASE SEVERITY; DRUG RESISTANCE; EPIDEMIC; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MORTALITY; RODENT; TUBERCULOSIS; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST DIRECTED THERAPY; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; MORTALITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERFERON TYPE I; INTERLEUKIN-1; MALE; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84903750131     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13489     Document Type: Article

References (33)

1. WHO. Tuberculosis Fact sheet Nu104. http://www.who.int/mediacentre/ factsheets/fs104/en/index.html (2012).
2. Russell, D. G., Barry, C. E. III&Flynn, J. L.Tuberculosis:whatwe don't knowcan, and does, hurt us. Science 328, 852-856 (2010).
3. Bishai, W., Sullivan, Z., Bloom, B. R.&Andersen, P. BetteringBCG: a tough task for a TB vaccine? Nature Med. 19, 410-411 (2013).
4. Lawn, S. D. & Zumla, A. I. Tuberculosis. Lancet 378, 57-72 (2011).
5. Gandhi, N. R. et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375, 1830-1843 (2010).
6. Nathan, C. Fresh approaches to anti-infective therapies. Sci. Transl. Med. 4, 140sr142 (2012).
7. Kaufmann, S. H. & Dorhoi, A. Inflammation in tuberculosis: interactions, imbalances and interventions. Curr. Opin. Immunol. 25, 441-449 (2013).
8. Mayer-Barber, K. D. et al. Innate and adaptive interferons suppress IL-1a and IL-1b production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35, 1023-1034 (2011).
9. Mayer-Barber, K. D. et al. Caspase-1 independent IL-1b production is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signaling in vivo. J. Immunol. 184, 3326-3330 (2010).
10. Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nature Rev. Immunol. 8, 349-361 (2008).
11. Bafica, A. et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Invest. 115, 1601-1606 (2005).
12. Chen, M. et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J. Exp. Med. 205, 2791-2801 (2008).
13. Divangahi, M. et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nature Immunol. 10, 899-906 (2009).
14. Kirtikara, K. et al. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J. Exp. Med. 187, 517-523 (1998).
15. Antonelli, L. R. et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest. 120, 1674-1682 (2010).
16. Rayamajhi, M.,Humann, J., Kearney,S., Hill, K. K.&Lenz, L. L.Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections. Virulence 1, 418-422 (2010).
17. Manca, C. et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-a/b. Proc. Natl Acad. Sci. USA 98, 5752-5757 (2001).
18. Stanley, S. A., Johndrow, J. E., Manzanillo, P. & Cox, J. S. The type I IFN response to infection with Mycobacteriumtuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 178, 3143-3152 (2007).
19. O'Garra, A. et al. The immune response in tuberculosis. Annu. Rev. Immunol. 31, 475-527 (2013).
20. Berry, M. P. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010).
21. Maertzdorf, J. et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 12, 15-22 (2011).
22. Ottenhoff, T. H. et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 7, e45839 (2012).
23. Barry, C. E. III et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845-855 (2009).
24. Law, K. et al. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 153, 799-804 (1996).
25. Tsao, T. C. et al. Increased TNF-alpha, IL-1 beta and IL-6 levels in the bronchoalveolar lavage fluid with the upregulation of theirmRNAin macrophages lavaged from patients with active pulmonary tuberculosis. Tuber. Lung. Dis. 79, 279-285 (1999).
26. Kuo, H. P. et al. Nitric oxidemodulates interleukin-1betaandtumornecrosis factoralpha synthesis by alveolarmacrophages in pulmonary tuberculosis.Am. J. Respir. Crit. Care Med. 161, 192-199 (2000).
27. Wang, C. H. & Kuo, H. P. Nitric oxide modulates interleukin-1beta and tumour necrosis factor-alpha synthesis, and disease regression by alveolar macrophages in pulmonary tuberculosis. Respirology 6, 79-84 (2001).
28. Rousu, J., Agranoff, D. D., Sodeinde, O., Shawe-Taylor, J. & Fernandez-Reyes, D. Biomarker discovery by sparse canonical correlation analysis of complex clinical phenotypes of tuberculosis and malaria. PLOS Comput. Biol. 9, e1003018 (2013).
29. Tobin, D. M. et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140, 717-730 (2010).
30. Tobin, D. M. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434-446 (2012).
31. Andrade, B. B. et al. Plasma heme oxygenase-1 levels distinguish latent or successfully treated human tuberculosis from active disease. PLoS ONE 8, e62618 (2013).
32. Humason, G. L. in Animal Tissue Techniques Ch. 20, 355 (W. H. Freeman, 1979).
33. Redford, P. S. et al. Influenza A virus impairs control of Mycobacterium tuberculosis co-infection through a type I interferon receptor dependent pathway. J. Infect. Dis. 209, 270-274 (2014).